7 Best Stocks for the Next 30 Days

Get them in a free Special Report, and get more Zacks Insights in our free e-newsletter, Profit from the Pros. Every issue includes a fresh Zacks #1 Bull Stock of the Day.

Close This Panel X

Are you a new Zacks Member or a visitor to Zacks.com?

Recent Quotes

No Recent Quote currently available

My Portfolio

My Portfolio Tracker

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Stocks on the Move 05/21/2013

Company Name Symbol %Change
SCIENTIFIC L SCIL
8.00%
NATUS MEDICA BABY
6.11%
SUMMER INFAN SUMR
6.02%
RADIANT LOGI RLGT
5.32%
NEW ORIENTAL EDU
4.51%

TDG Beats Estimate, Ups Guidance

by Zacks Equity Research

May 09, 2012 | Comments : 0 Recommended this article: (0)

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

TransDigm Group Incorporated ( TDG - Analyst Report ) reported second-quarter fiscal 2012 earnings per share from continuing operations of $1.51, outpacing the Zacks Consensus Estimate of $1.30 and prior-year earnings per share of 69 cents.

Revenue

Net sales were $423.5 million, up 39.2% year over year. Organically, sales during the quarter surged approximately 14.9%, driven by increased sales in commercial OEM markets and aided by acquisitions of Schneller, Harco and Amsafe.

Income & Expenses

Income from operations for the quarter was $177.2 million compared with $113.2 million in the prior-year period. Selling and administrative expenses were $49.5 million compared with $33.2 million in the comparable quarter last year. EBITDA for the quarter jumped $192.5 million from $128.3 million.

Balance Sheet & Cash Flow

Cash and cash equivalents were $201.5 million at the end of the quarter compared with $376.2 million at the end of fiscal 2011. Long-term debt was $3.6 billion while shareholders equity was $994.9 million at the end of the quarter.

Net cash from operating activities was $164.8 million in the quarter compared with $129.2 million in the prior-year period.

Outlook

Driven by the robust performance in the second quarter, the company raised its full year 2012 guidance. TransDigm expects its total revenue for fiscal 2012 to be in the range of $1,670 million to $1,698 million, up from its prior guidance range of $1,470 million to $1,510 million. Further, earnings per share are expected to be in the range of $5.47 to $5.82, up from its prior guidance of $5.15 to $5.49. Adjusted earnings per share are expected to be in the range of $6.23 to $6.57, up from its prior guidance range of $5.66 to $6.00.

The company revised its guidance to account for the recent acquisition of AmSafe and good performance in the first half of the year. However, uncertain aerospace market and worldwide economic environment remain a matter of concern.

Based in Cleveland, Ohio, TransDigmGroup Inc.designs, produces, and supplies engineered aircraft components for use on commercial and military aircraft. The company operates principally in the US. Major competitors of the company are Goodrich Corp. ( ) , Honeywell International Inc. ( HON - Analyst Report ) and United Technologies Corp. ( UTX - Analyst Report ) .

We continue to maintain an Outperform rating on TranDigm for the long term. The company has a Zacks #1 Rank (Strong-Buy recommendation) over the next one-to-three months.

Email Print Share Rate Pos Rate Neg

Read/Post Comments (0) | Recommended this article (0)

Please login to Zacks.com or register to post a comment.

Zacks Research is Reported On:

Zacks Investment Research

is an A+ Rated BBB

Accredited Business.